Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Effectiveness and acceptability of sertraline and citalopram in major depressive disorder: pragmatic randomized open-label comparison.
OBJECTIVE Citalopram and sertraline are widely prescribed selective serotonin reuptake inhibitors ( SSRIs ) . There is no conclusive evidence to show superiority of citalopram or sertraline in terms of efficacy or tolerability . Hence this study was design ed to compare short term efficacy and safety of citalopram and sertraline in major depressive disorder ( MDD ) in Indian patients . METHODS In an open , r and omized study , 100 patients were divided into two groups . In Group A ( n = 50 ) patients received citalopram ( 20 - 60 mg/day ) for 6 weeks . In Group B ( n = 50 ) patients received sertraline ( 50 - 150 mg/day ) for 6 weeks . Patients were evaluated at baseline and then at 1 , 2 , 3 , 4 , 5 , and 6 weeks . RESULTS There was significant improvement in Hamilton depression rating scale ( HDRS ) , Montgomery and Asberg depression rating scale ( MADRS ) and Amritsar depressive inventory ( ADI ) scores ( p < 0.05 ) with both the drugs . However , the decrease in score was more with citalopram ( p < 0.05 ) . Onset of action of citalopram  was earlier as compared to sertraline ( p < 0.05 ) . The number of responders and remitters was also more with citalopram ( p < 0.05 ) . No serious adverse event was reported in either of the groups . CONCLUSION Citalopram had shown better efficacy , earlier onset of action and more number of responders and remitters as compared to sertraline in MDD in Indian patients
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .